
- Psychiatric Times Vol 28 No 6
- Volume 28
- Issue 6
Introduction: Comorbidity, Cognition, and Pharmacotherapies
In this Special Report, Helen M. Pettinati, PhD, and William D. Dundon, PhD, discuss prevalence, assessment, clinical features, and treatment issues with respect to individuals with co-occurring major depression and alcohol dependence.
Substance use disorders are arguably a leading category of health problems in the United States. Of the proposed top 5 health problems in terms of economic costs (in decreasing order: drug abuse, mental illness, heart disease, alcohol use disorders, and nicotine use), 3 are substance use disorders.1 Substance use disorders are commonly encountered in every domain of psychiatric practice. Yet psychiatrists often feel limited in their ability to recognize and manage these disorders. In this Special Report, accomplished authors provide focal reviews on topics central to the psychiatric treatment of substance use disorders.
Cognitive dysfunction, particularly fronto-executive deficits, has increasingly been recognized as problematic for patients with substance use disorders. Not only may there be preexisting trait-dependent deficits that portend risk for the onset of addiction disorder, but also there has been increasing interest in the pathophysiology and progression of state-dependent cognitive deficits that negatively impact the clinical course. We now understand that in addition to pathology in the reward, motivation, and memory/learning circuits, addiction disorders are characterized by dysfunctional cognition/decision-making circuits wherein the brain overvalues reward, undervalues risk, and fails to learn from repeated errors.4
Despite evidence for efficacy, medications continue to be underused in the treatment of alcohol dependence. A “double-whammy” often exists in clinical practice when depression and alcohol dependence co-occur. Not only may providers not offer medications for alcohol dependence, but they may also be reluctant to prescribe medication for depression until they are assured that the symptoms of depression are not substance-induced. Often, however, the net effect is that the patient ei-ther leaves treatment or the clini-cian fails to follow up on the option of medication-and opportunities are lost. Given that comorbid depression is considered one of the strongest relapse risk predictors for alcohol dependence, the results can be disastrous.
In this Special Report,
We are hopeful that you will find these articles practical and helpful, ideally assisting you in the translation of research into clinical practice.
Disclaimer-The contents do not represent the views of the Department of Veterans Affairs or the United States government.
References:
References
1. Office of National Drug Control Policy. The Economic Costs of Drug Abuse in the United States, 1992-2002. Washington, DC: Executive Office of the President; 2004. Publication 207303.
2. Knudsen HK, Roman PM, Oser CB. Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizations. J Addict Med. 2010;4:99-107.
3. Knudsen HK, Abraham AJ, Roman PM. Adoption and implementation of medications in addiction treatment programs. J Addict Med. 2011;5:21-27.
4. Volkow ND, Baler RD, Goldstein RZ. Addiction: pulling at the neural threads of social behaviors. Neuron. 2011;69:599-602.
Articles in this issue
over 14 years ago
Feeling Socially Safeover 14 years ago
Avoiding SRI Discontinuation Syndromeover 14 years ago
Drs McGlashan and Woods Respond to Dr Feinbergover 14 years ago
Obama Drug Misuse Strategy Targets Physician Educationover 14 years ago
Alfred M. Freedman, MD, 1917-2011over 14 years ago
Is It Treatment-Refractory Schizophrenia . . . And if It Is?over 14 years ago
Are We Training Psychiatrists to Provide Only Medication Management?over 14 years ago
Effects of Early Parental DepressionNewsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.